UK biotech sector welcomes government's EU trade proposals

Following the UK’s publication of its proposed Brexit deal, the country’s biotech industry has issued a statement interpreting the likely impact for the sector, noting a range of effects from the UK’s relationship with the European Medicines Agency, to intellectual property (IP) protection and other legal issues.

In its statement, the UK Bioindustry Association (BIA) says: “Over the last two years, BIA has consistently advocated that government pursue a number of policies essential to members and industry as well as patients and public health.”

“It is good to see much of this reflected in the white paper and it shows that the UK government has listened to the needs of patients, public health and the UK life science ecosystem.”